SonoVascular - Lightning Pitch

Why It Matters

The platform promises to transform clot treatment by delivering rapid, blood‑loss‑free therapy in a cath‑lab, potentially lowering healthcare costs and expanding access to safer thrombectomy.

Key Takeaways

• SonoVascular’s system combines ultrasound, microbubbles, and thrombolytics for treatment.
• Catheter delivers focused ultrasound at tip for clot fragmentation.
• First human DVT study shows complete clot resolution, no blood loss.
• FDA meetings secured Class II de novo pathway and pivotal study alignment.
• Procedure performed in cath lab, avoiding ICU stay and vascular trauma.

Summary

In a lightning‑pitch presentation, Dan Estee, CEO and founder of SonoVascular, introduced a novel catheter‑based system that uses focused ultrasound, microbubbles and a thrombolytic drug to treat blood clots.

The device delivers ultrasound through the catheter tip while simultaneously infusing microbubbles and medication, fragmenting and dissolving clots in a cath‑lab setting. A first‑in‑human study in deep‑vein thrombosis reported near‑complete clot resolution, no measurable blood loss, and six‑month durability, positioning the therapy as a safer alternative to surgical or ICU‑based approaches.

Estee emphasized that the system “delivers more precise, better, safer clot clearance,” highlighting the absence of vascular trauma. The company has met the FDA twice, receiving agreement on a Class II de novo pathway and the design of a pivotal trial.

If successful, the technology could shift clot management from invasive surgery and intensive care to outpatient cath‑lab procedures, reducing costs, shortening hospital stays, and opening a sizable market for ultrasound‑guided thrombectomy.